Format

Send to

Choose Destination
J Pediatr Gastroenterol Nutr. 2015 May;60(5):578-9. doi: 10.1097/MPG.0000000000000765.

Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.

Author information

1
*Department of Pediatrics †Department of Radiology, Ohio State University College of Medicine, Columbus.

Abstract

Treatment of liver disease, including hepatic steatosis, in patients with cystic fibrosis (CF) is limited. With the development of ivacaftor, which corrects the gating defect of the CF transmembrane regulator channel, there is a potential new therapy available for this subgroup of the CF patient population. We present an adolescent with CF who had significant improvement in hepatic steatosis with ivacaftor treatment while hypothesizing on a mechanism of why it occurred.

PMID:
25688481
DOI:
10.1097/MPG.0000000000000765
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center